UNICREDIT BANK/CALL/ELI LILLY & CO/1150/0.1/18.12.24 | Real-time BOERSE MUENCHEN 03:10:23 06/06/2024 pm IST | ||
| 1.15 EUR | 0.00% |
|
| Current month | +17.35% | ||
| 1 month | +144.68% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 06/24/06 | 1.15 | 0.00% |
| 05/24/05 | 1.15 | 0.00% |
| 04/24/04 | 1.15 | +2.68% |
| 03/24/03 | 1.12 | +14.29% |
| 31/24/31 | 0.98 | -2.97% |
Real-time BOERSE MUENCHEN
Last update June 06, 2024 at 03:10 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD4LBM |
| ISIN | DE000HD4LBM9 |
| Date issued | 12/04/2024 |
| Strike | 1,150 $ |
| Maturity | 18/12/2024 (196 Days) |
| Parity | 10 : 1 |
| Emission price | 1.11 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.21 € |
|---|---|
| Lowest since issue | 0.47 € |
| Spread | 0.25 € |
| Spread % | 19.84% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
831.8
USD
Average target price
852.5
USD
Spread / Average Target
+2.50%
- Stock Market
- Warrants
- Warrant
